NUVB:NYE-Nuvation Bio Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 2.24

Change

+0.07 (+3.23)%

Market Cap

USD 0.56B

Volume

2.40M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
TECH Bio-Techne Corp

+0.13 (+0.26%)

USD 8.03B
BHVN Biohaven Pharmaceutical Holdin..

-0.27 (-1.69%)

USD 1.64B
RCUS Arcus Biosciences Inc

+0.15 (+1.75%)

USD 0.91B
DNA Ginkgo Bioworks Holdings

+0.16 (+2.02%)

USD 0.46B
CYBN Cybin Inc

+0.78 (+11.61%)

USD 0.15B
ADCT ADC Therapeutics SA

+0.45 (+23.81%)

USD 0.14B
PLX Protalix Biotherapeutics Inc

+0.01 (+0.60%)

USD 0.13B
OSTX OS Therapies Incorporated

-0.05 (-3.05%)

USD 0.07B
ANRO Alto Neuroscience, Inc.

+0.01 (+0.40%)

USD 0.07B
ATNM Actinium Pharmaceuticals Inc

+0.12 (+7.19%)

USD 0.05B

ETFs Containing NUVB

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.79% 58% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.79% 58% F 12% F
Trailing 12 Months  
Capital Gain -34.31% 74% C 8% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.31% 74% C 8% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.83% 37% F 7% C-
Dividend Return -9.83% 37% F 6% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 58.27% 60% D- 13% F
Risk Adjusted Return -16.87% 34% F 14% F
Market Capitalization 0.56B 93% A 50% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector